Mersana Therapeutics, Inc. (MRSN) Debt by Year
Mersana Therapeutics, Inc. carried $10.9M in long-term debt against $107.8M in cash and equivalents at the end of fiscal year 2024. This represents a decrease of 52.7% from the prior fiscal year. The table below carries 10 fiscal years, from 2015 to 2024, and the quarters Mersana Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
MRSN Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K |
|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $10.9M-52.7% | $23.1M-7.1% | $24.9M+1.2% | $24.6M+394.8% | $5.0M+18.5% | $4.2M | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $107.8M-38.3% | $174.6M+35.4% | $128.9M-27.6% | $177.9M-30.2% | $255.1M+309.1% | $62.4M+4.6% | $59.6M+124.3% | $26.6M-73.5% | $100.3M+769.6% | $11.5M |
MRSN Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $0-100.0% | $0-100.0% | $7.9M-60.1% | $10.9M-52.7% | $14.0M-44.0% | $17.0M-31.8% | $19.8M-20.8% | $23.1M-7.1% | $25.0M0.0% | $25.0M0.0% | $25.0M0.0% | $24.9M+1.2% |
| Cash & Equivalents | $56.4M-28.5% | $77.0M+30.5% | $102.3M+36.0% | $107.8M-38.3% | $78.9M-57.7% | $59.0M-54.2% | $75.2M-38.8% | $174.6M+35.4% | $186.3M+1.2% | $128.7M-4.9% | $122.8M-46.6% | $128.9M-27.6% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Mersana Therapeutics, Inc. financials
Frequently Asked Questions
What was Mersana Therapeutics, Inc.'s long-term debt in fiscal year 2024?
Mersana Therapeutics, Inc. carried $10.9M in long-term debt against $107.8M in cash and equivalents at the end of fiscal year 2024.
How fast is Mersana Therapeutics, Inc.'s long-term debt growing?
Mersana Therapeutics, Inc. (MRSN) long-term debt fell by 52.7% year over year, from $23.1M to $10.9M in fiscal year 2024.
What was Mersana Therapeutics, Inc.'s long-term debt in the most recent quarter?
Mersana Therapeutics, Inc. (MRSN) reported $0 in long-term debt in Q3 2025. This represents a decrease of 100.0% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Mersana Therapeutics, Inc. (MRSN) reported on that line in every period on record.